MedTrace Logo

Dutch Cangrelor Registry

NCT04138641 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2020-07-28

No results posted yet for this study

Summary

Cangrelor is a fast and directly acting platelet aggregation inhibitor. It is potentially indicated for several types of patients who are undergoing PCI. A nationwide cangrelor registry has up until now not been performed and with the introduction of cangrelor in the Netherlands its efficacy and safety will be determined.

Conditions

Interventions

DRUG

Cangrelor

Cangrelor intravenous

Sponsors & Collaborators

  • Isala

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-17
Primary Completion
2020-07-24
Completion
2020-07-24
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04138641 on ClinicalTrials.gov